Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation

International Journal of Molecular Medicine

Volumn 28, Issue 6, 2011, Pages 1049-1053

  Yamaguchi, Masayoshi ^b   Arbiser, Jack L ^a,b   Weitzmann, M Neale ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Honokiol; Nuclear factor B; Osteoblast; Osteoporosis

Indexed keywords

ANABOLIC AGENT; BONE MORPHOGENETIC PROTEIN 2; HONOKIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMAD PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; DRUGS, CHINESE HERBAL; HUMANS; LIGNANS; MAGNOLIA; MICE; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053468944     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.786     Document Type: Article

References (34)

1. Teitelbaum SL: Bone resorption by osteoclasts. Science 289: 1504-1508, 2000.
2. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055, 2001.
3. Boyce BF, Yao Z and Xing L: Functions of nuclear factor kappaB in bone. Ann NY Acad Sci 1192: 367-375, 2010.
4. Hall TJ, Schaeublin M, Jeker H, Fuller K and Chambers TJ: The role of reactive oxygen intermediates in osteoclastic bone resorption. Biochem Biophys Res Commun 207: 280-287, 1995.
5. Yamaguchi M and Weitzmann MN: Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int J Mol Med 27: 3-14, 2011.
6. Feng R, Anderson G, Xiao G, et al: SDX-308, a nonsteroidal anti-in.ammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 109: 2130-2138, 2007. (Pubitemid 46348215)
7. Clohisy JC, Hirayama T, Frazier E, Han SK and Abu-Amer Y: NF-κB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res 22: 13-20, 2004. (Pubitemid 38035440)
8. Strait K, Li Y, Dillehay DL and Weitzmann MN: Suppression of NF-κB activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med 21: 521-525, 2008. (Pubitemid 351802648)
9. Dai S, Hirayama T, Abbas S and Abu-Amer Y: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in in.ammatory arthritis. J Biol Chem 279: 37219-37222, 2004. (Pubitemid 39195425)
10. Li Y, Li A, Strait K, Zhang H, Nanes MS and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic smad activation, through NF-kappaB. J Bone Miner Res 22: 646-655, 2007. (Pubitemid 351339092)
11. Yamaguchi M and Weitzmann MN: The bone anabolic carotenoids p-hydroxycinnamic acid and β-cryptoxanthin antagonize NF-κB activation in MC3T3 preosteoblasts. Mol Med Rep 2: 641-644, 2009.
12. Yamaguchi M and Weitzmann MN: The estrogen 17β-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-κB activity. Int J Mol Med 23: 297-301, 2009.
13. Gilbert L, He X, Farmer P, et al: Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277: 2695-2701, 2002. (Pubitemid 34953297)
14. Kaneki H, Guo R, Chen D, et al: Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281: 4326-4333, 2006. (Pubitemid 43847863)
15. Guo R, Yamashita M, Zhang Q, et al: Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 283: 23084-23092, 2008.
16. Chang J, Wang Z, Tang E, et al: Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15: 682-689, 2009.
17. Alles N, Soysa NS, Hayashi J, et al: Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology 151: 4626-4634, 2010.
18. Wahl EC, Aronson J, Liu L, et al: Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF. J Bone Miner Res 25: 114-123, 2010.
19. Wahl EC, Aronson J, Liu L, et al: Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice. Bone 46: 410-417, 2010.
20. Fried LE and Arbiser JL: Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 11: 1139-1148, 2009.
21. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL and Aggarwal BB: Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 4: 621-633, 2006. (Pubitemid 44497215)
22. Kim KR, Park KK, Chun KS and Chung WY: Honokiol inhibits the progression of collagen-induced arthritis by reducing levels of pro-in.ammatory cytokines and matrix metalloproteinases and blocking oxidative tissue damage. J Pharmacol Sci 114: 69-78, 2010.
23. Yamaguchi M and Weitzmann MN: The bone anabolic carotenoid β-cryptoxanthin enhances transforming growth factor-β1-induced SMAD activation in MC3T3 preosteoblasts. Int J Mol Med 24: 671-675, 2009.
24. Sugimoto E and Yamaguchi M: Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. Int J Mol Med 5: 515-520, 2000.
25. Andrews NC and Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499, 1991.
26. Nanes MS: Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321: 1-15, 2003.
27. Xing L, Bushnell TP, Carlson L, et al: NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokinemediated osteoclastogenesis. J Bone Miner Res 17: 1200-1210, 2002. (Pubitemid 34680496)
28. Novack DV, Yin L, Hagen-Stapleton A, et al: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198: 771-781, 2003. (Pubitemid 37087776)
29. Janssens K, Ten Dijke P, Janssens S and Van Hul W: Transforming growth factor-beta1 to the bone. Endocr Rev 26: 743-774, 2005.
30. Tang Y, Wu X, Lei W, et al: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15: 757-765, 2009.
31. Wan M and Cao X: BMP signaling in skeletal development. Biochem Biophys Res Commun 328: 651-657, 2005. (Pubitemid 40208302)
32. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H and Rosier RN: Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res 312: 40-50, 2006. (Pubitemid 41668590)
33. McClung MR, Lewiecki EM, Cohen SB, et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831, 2006. (Pubitemid 43290920)
34. Hodsman AB, Bauer DC, Dempster DW, et al: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688-703, 2005. (Pubitemid 41127277)